Edition:
United Kingdom

Concert Pharmaceuticals Inc (CNCE.OQ)

CNCE.OQ on NASDAQ Stock Exchange Global Market

21.64USD
3:56pm GMT
Change (% chg)

$0.52 (+2.46%)
Prev Close
$21.12
Open
$21.09
Day's High
$21.81
Day's Low
$21.09
Volume
14,082
Avg. Vol
135,549
52-wk High
$30.70
52-wk Low
$9.04

Select another date:

Mon, Feb 12 2018

BRIEF-Concert Pharmaceuticals Initiates Enrollment In Second Cohort Of CTP-543 Trial

* CONCERT PHARMACEUTICALS ANNOUNCES INITIATION OF ENROLLMENT IN SECOND COHORT OF CTP-543 PHASE 2A TRIAL FOR ALOPECIA AREATA

BRIEF-Concert Pharma Says FDA Granted Fast Track Designation To CTP-543

* FDA GRANTS FAST TRACK DESIGNATION TO CONCERT PHARMACEUTICALS’ CTP-543 FOR THE TREATMENT OF ALOPECIA AREATA

BRIEF-Concert Pharmaceuticals Announces Patent Trial And Appeal Board Did Not Institute PGR Proceeding

* CONCERT PHARMACEUTICALS ANNOUNCES PATENT TRIAL AND APPEAL BOARD DID NOT INSTITUTE PGR PROCEEDING Source text for Eikon: Further company coverage:

BRIEF-Concert Pharmaceuticals Announces Appointment Of Marc Becker As CFO

* CONCERT PHARMACEUTICALS ANNOUNCES THE APPOINTMENT OF MARC BECKER AS CHIEF FINANCIAL OFFICER

BRIEF-Concert Pharmaceuticals reports Q3 earnings per share $5.61

* Concert Pharmaceuticals reports third quarter 2017 financial results and provides company update

BRIEF-Concert Pharmaceuticals announces completion of enrollment in First Cohort of CTP-543 phase 2a trial

* Concert Pharmaceuticals Inc announces completion of enrollment in First Cohort of CTP-543 phase 2a trial

BRIEF-Concert Pharma pays total of $30.8 mln to Hercules Capital

* Concert Pharmaceuticals- ‍on Sept 7, paid total of $30.8 million to hercules capital outstanding under loan and security agreement with Hercules dated June 8

Select another date: